RUNX1 and myeloid neoplasm: It is estimated that ∼40% of individuals diagnosed with FPD/AML will develop a myeloid neoplasm, since germline RUNX1 variants alone are insufficient to induce AML, and that second-hit mutational events are necessary [8,9].